MIFH
CYTK icon

Migdal Insurance & Financial Holdings’s Cytokinetics CYTK Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-284
Closed -$18K – 373
2025
Q4 		$18K Buy
+284
New +$17.7K ﹤0.01% 315

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Migdal Insurance & Financial Holdings's CYTK Position: Q1 2026 in Review

Migdal Insurance & Financial Holdings sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 284 shares — an estimated $18K sold.

Migdal Insurance & Financial Holdings first reported a position in CYTK in Q4 2025 and held it in 1 quarter. The position peaked at $18K in Q4 2025. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Migdal Insurance & Financial Holdings reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 284 Cytokinetics shares in Q1 2026, an estimated $18K.
  • Migdal Insurance & Financial Holdings first reported a position in Cytokinetics in Q4 2025 and held it in 1 quarter.
  • Migdal Insurance & Financial Holdings's Cytokinetics position peaked at $18K in Q4 2025.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2026, filed 14 May 2026.